

GelX[®] Oral Spray

for both the treatment & prevention of Oral Mucositis¹



Effective

Pain relief and reduces inflammation, ingredients include Zinc and Taurine



Convenient

Simple application and ready to use



Cost Effective

Significant potential savings vs competitor treatments



GelX®: Help patients take control

- Provides a bio-adhesive barrier for durable protection
- Blocks exposed nerve endings and coats oral lesions to soothe and relieve pain^{1,3}
- GelX® Aids patients in coping with OM and completing long-term treatment goals





- GelX® Oral Spray helps prevent mucositis and promotes healing
- GelX® Oral Spray helps remove pain caused by oral mucositis during high-risk chemotherapy in children with cancer
- The severity of oral mucositis (WHO scale) was improved
- Duration of mucositis was shorter after including GelX® Oral Spray in the treatment

- Swallowing and eating difficulties were reduced, comparing with mucositis symptoms from previous cycles treated with the same therapeutic measures, but without GelX® Oral Spray
- There were no delays in treatment caused by severity of oral mucositis

Cost Comparison



Product	List Price⁴	Recommended Dose	Monthly Cost	Daily Cost
GelX Oral Spray 100ml	£49.21	3 sprays 3 times per day	£49.21	£1.64
Caphosol 30 Doses	£34.28	1 Dose 4-10 times daily	£137.10 - £342.90	£4.57 - £11.43
Caphosol 120 doses	£130.70	1 Dose 4-10 times daily	£130.80 - £326.70	£4.36 - £10.89
Gelclair 21 Sachets	£34.76	3 sachets per day	£149.10	£4.97

Monthly Cost is based on 30 days

Ordering

GELX is a registered trademark of Sunstar Suisse SA.

For any queries regarding ordering please contact: customer.services@galen-pharma.com

Galen Limited

Seagoe Industrial Estate Craigavon BT63 5UA United Kingdom



References

- 1. Gel X Oral Spray Instructions for Use.
- 2. Data on File, Galen.
- 3. Biswal BM. Current trends in the management of oral mucositis related to cancer treatment Malaysian J Med Sci. 2008;15(3):4-13.
- 4. MIMS online. Accessed August 2022.
- 5 Niculita. The efficacy of Polyvynilpyrrolidone-Zn Gluconate and Taurine in the Prevention of Oral Mucositis in Haematological Patients. 2020.

Adverse incidents should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse incidents should also be reported to Galen Limited on 028 3833 4974 and select the customer services option, or e-mail customer.services@galen-pharma.com Medical information enquiries should also be directed to Galen Limited.

PIP Code: 413-6198

MAT-GELX OS-UK-000068

Date of Preparation: February 2023

